Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 247 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Adult Male Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Bosutinib In Subjects With Renal Impairment

NCT01233882
View directory record Official record
Conditions
Renal Disease, End-Stage, Renal Insufficiency, Chronic, Renal Insufficiency, Acute
Interventions
Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
5
States / cities
DeLand, Florida • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 2, 2026, 2:04 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

NCT07168356
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 2, 2026, 2:04 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects

NCT00449709
View directory record Official record
Conditions
Obstetric Labour, Premature, Premature Ejaculation
Interventions
GSK221149
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

NCT06586216
View directory record Official record
Conditions
COVID-19
Interventions
PF-07817883
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALXN2050 in Participants With Renal Impairment

NCT04623710
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
ALXN2050
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 2, 2026, 2:04 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

NCT07242781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986365, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

NCT00647712
View directory record Official record
Conditions
Healthy
Interventions
Divalproex Sodium Extended-Release Tablets 500 mg, Depakote ER® Tablets 500 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

NCT02412449
View directory record Official record
Conditions
Healthy
Interventions
AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 2, 2026, 2:04 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

NCT05280717
View directory record Official record
Conditions
Covid19
Interventions
sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study of Adults With Autism Spectrum Disorders

NCT01093768
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Oxytocin, Vasopressin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Partnership for Healthy Seniors

NCT00379743
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Cancer, Prostate Cancer
Interventions
Health coordinator (or patient navigator), Educational materials only
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
65 Years and older
Enrollment
2,593 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

NCT04849650
View directory record Official record
Conditions
Renal Disease, End Stage
Interventions
Amisulpride IV, Amisulpride Oral Tablet
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

NCT01183676
View directory record Official record
Conditions
Healthy
Interventions
DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389
View directory record Official record
Conditions
Alzheimer Disease
Interventions
300 mg [C14] CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.

NCT03202693
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid

NCT00343148
View directory record Official record
Conditions
Neoplasms
Interventions
AVI-4126 Injection (RESTEN-NG®)
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects

NCT02448212
View directory record Official record
Conditions
Healthy
Interventions
TS-121, [11C]TASP0410699, Positron Emission Tomography (PET)
Drug · Radiation
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

NCT02049528
View directory record Official record
Conditions
Clinical Pharmacology, Healthy Male Volunteer Study
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

NCT01776437
View directory record Official record
Conditions
Human Volunteers
Interventions
BMN 673
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Two Different Lion's Mane Extracts (Lions Mane Fruiting Body & Lions Mane Fruiting Body With Mycellium) on Cognitive Performance, Subjective Affect, Serum Biomarkers, and Gut Microbiota in Healthy Adults

NCT07405957
View directory record Official record
Conditions
Healthy Adult Females, Healthy Adult Male
Interventions
Lion Mane (Hericium erinaceus) fruiting body extract - Nordic Origin, Lions Mane (Hericium erinaceus) Fruiting body and mycelium, Maltodextrin (Placebo)
Dietary Supplement · Other
Lead sponsor
Applied Food Sciences Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

NCT01915212
View directory record Official record
Conditions
Healthy Volunteers
Interventions
HSV529, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

NCT05074134
View directory record Official record
Conditions
Healthy
Interventions
[14C]-TNP-2092
Drug
Lead sponsor
TenNor Therapeutics Limited
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 2, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

NCT04092712
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 2, 2026, 2:04 AM EDT